NCT03271580

Brief Summary

The purpose of this study is to learn more about biofilm and to see how it affects diabetic wounds. A biofilm can occur if a chronic infection causes bacteria to grow in a slime enclosed group. This grouping of bacteria is called a biofilm.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
31

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Feb 2020

Geographic Reach
1 country

5 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 12, 2017

Completed
3 months until next milestone

First Posted

Study publicly available on registry

September 5, 2017

Completed
2.4 years until next milestone

Study Start

First participant enrolled

February 1, 2020

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 13, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 13, 2021

Completed
Last Updated

April 25, 2024

Status Verified

April 1, 2024

Enrollment Period

1.6 years

First QC Date

June 12, 2017

Last Update Submit

April 23, 2024

Conditions

Keywords

Wound healingDiabetesInflammatory cellsMacrophage

Outcome Measures

Primary Outcomes (2)

  • Biofilm infection

    Biofilm Infection using SEM and RT PCR analysis

    14 Weeks

  • macrophage phenotyping

    Wound macrophage phenotypes using flowcytometry, RTPCR and RNA Seq

    14 Weeks

Study Arms (2)

Diabetic patients infected ulcers

Diabetic patients with HbA1c\<9 with who have wound 4weeks or longer with infection with following interventions: 1. Finger prick test for HbA1c measurement 2. Punch biopsy 3. VAC sponge collection 4. Ankle brachial index

Diagnostic Test: Finger prick test for HbA1c measurementProcedure: Punch BiopsyOther: Vac Sponge CollectionOther: Ankle Brachial Index

Diabetic patients non infected Ulcers

Diabetic patients with HbA1c\<9 who have wound 4 weeks or longer without infection with following interventions: 1. Finger prick test for HbA1c measurement 2. Punch biopsy 3. VAC sponge collection 4. Ankle brachial index

Diagnostic Test: Finger prick test for HbA1c measurementProcedure: Punch BiopsyOther: Vac Sponge CollectionOther: Ankle Brachial Index

Interventions

HbA1c measurement with finger prick method

Diabetic patients infected ulcersDiabetic patients non infected Ulcers
Punch BiopsyPROCEDURE

Wound site will be anaesthetized, by punch biopsy tissue will be collected, wound site will be monitored for bleeding(if bleeding Cautery will be used to stop bleeding).

Diabetic patients infected ulcersDiabetic patients non infected Ulcers

NPWT sponge which is discarded as biological waste, will be collected for wound macrophage isolation

Diabetic patients infected ulcersDiabetic patients non infected Ulcers

Blood pressure test

Diabetic patients infected ulcersDiabetic patients non infected Ulcers

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Twenty-eight diabetic subjects with chronic foot ulcer(s) that are receiving Negative Wound Pressure Therapy (NPWT) will be enrolled. Eighteen subjects will be infected and 10 subjects will be non-infected serving as the control for the study. The inclusion and exclusion criteria were carefully selected to enroll diabetic patients who have wound tissue oxygenation adequate to support wound healing.

You may qualify if:

  • Age 18 and above years old
  • Willing and able to provide informed consent
  • Willing and able to comply with protocol instructions, including biopsies and study visits
  • Diabetics with an open wound
  • Receiving Negative Wound Pressure Therapy (NPWT)

You may not qualify if:

  • Inadequate arterial supply, as evidenced by any of the following (for wounds below the knee):
  • TcOM \< 30mmHg
  • ABI \< 0.7
  • TBI \< 0.6
  • Women who are pregnant

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (5)

IU Health Methodist Hospital

Indianapolis, Indiana, 46202, United States

Location

Davis Heart and Lung Institute

Columbus, Ohio, 42310, United States

Location

The Ohio State University Hospital East

Columbus, Ohio, 43203, United States

Location

Comprehensive Wound Care Centers, The Ohio State University Hospital

Columbus, Ohio, 43210, United States

Location

Martha Morehouse Medical Plaza

Columbus, Ohio, 43221, United States

Location

Related Publications (7)

  • Breen JD, Karchmer AW. Staphylococcus aureus infections in diabetic patients. Infect Dis Clin North Am. 1995 Mar;9(1):11-24.

    PMID: 7769212BACKGROUND
  • Davis SC, Martinez L, Kirsner R. The diabetic foot: the importance of biofilms and wound bed preparation. Curr Diab Rep. 2006 Dec;6(6):439-45. doi: 10.1007/s11892-006-0076-x.

    PMID: 17118226BACKGROUND
  • James GA, Swogger E, Wolcott R, Pulcini Ed, Secor P, Sestrich J, Costerton JW, Stewart PS. Biofilms in chronic wounds. Wound Repair Regen. 2008 Jan-Feb;16(1):37-44. doi: 10.1111/j.1524-475X.2007.00321.x. Epub 2007 Dec 13.

    PMID: 18086294BACKGROUND
  • Hanke ML, Angle A, Kielian T. MyD88-dependent signaling influences fibrosis and alternative macrophage activation during Staphylococcus aureus biofilm infection. PLoS One. 2012;7(8):e42476. doi: 10.1371/journal.pone.0042476. Epub 2012 Aug 3.

    PMID: 22879997BACKGROUND
  • Hanke ML, Heim CE, Angle A, Sanderson SD, Kielian T. Targeting macrophage activation for the prevention and treatment of Staphylococcus aureus biofilm infections. J Immunol. 2013 Mar 1;190(5):2159-68. doi: 10.4049/jimmunol.1202348. Epub 2013 Jan 30.

    PMID: 23365077BACKGROUND
  • Neut D, Tijdens-Creusen EJ, Bulstra SK, van der Mei HC, Busscher HJ. Biofilms in chronic diabetic foot ulcers--a study of 2 cases. Acta Orthop. 2011 Jun;82(3):383-5. doi: 10.3109/17453674.2011.581265. Epub 2011 May 11. No abstract available.

    PMID: 21561305BACKGROUND
  • Zhao G, Usui ML, Lippman SI, James GA, Stewart PS, Fleckman P, Olerud JE. Biofilms and Inflammation in Chronic Wounds. Adv Wound Care (New Rochelle). 2013 Sep;2(7):389-399. doi: 10.1089/wound.2012.0381.

    PMID: 24527355BACKGROUND

Biospecimen

Retention: SAMPLES WITH DNA

Blood, Wound Vac Sponge, Wound Tissue biopsy

MeSH Terms

Conditions

Wounds and InjuriesBacterial InfectionsDiabetes Mellitus

Condition Hierarchy (Ancestors)

Bacterial Infections and MycosesInfectionsGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Study Officials

  • Sashwati Roy, PhD

    Indiana University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

June 12, 2017

First Posted

September 5, 2017

Study Start

February 1, 2020

Primary Completion

September 13, 2021

Study Completion

September 13, 2021

Last Updated

April 25, 2024

Record last verified: 2024-04

Data Sharing

IPD Sharing
Will not share

Locations